Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate

Epilepsia

Volumn 52, Issue 10, 2011, Pages 1877-1883

  Lambrecht, Lawrence J ^a   Shekh Ahmad, Tawfeeq ^b   Todd, Wesley M ^a   Halvorsen, Mark B ^a   Bialer, Meir ^b  

^a Upsher Smith Laboratories Inc   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Food effect; Healthy subjects; New topiramate extended release formulation; Pharmacokinetics; USL255

Indexed keywords

ANTICONVULSIVE AGENT; TOPIRAMATE; UNCLASSIFIED DRUG; USL 255;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DIZZINESS; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; FRUCTOSE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 80053574023     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2011.03183.x     Document Type: Article

References (25)

1. Almeida L, Bialer M, Soarez-da-Sliva P, (2009) Eslicarbazepine acetate. In, Shorvon S, Perucca E, Engel J, (Eds) The treatment of epilepsy. 3rd ed. Wiley-Blackwell, Oxford, U.K., pp. 485-498.
2. Bialer M,. (2007) Extended release formulations for the treatment of epilepsy. CNS Drugs 21: 765-771.
3. Bialer M, Arcavi L, Sussan S, Volosov A, Yacobi A, Moros D, Levitt B, Laor A,. (1998) Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine. Epilepsy Res 32: 371-378. (Pubitemid 28518243)
4. Bialer M, Doose DR, Murthy B, Curtin C, Wang S-S, Twyman RE, Schwabe S,. (2004) Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 43: 763-788.
5. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T,. (2007) Progress report on new antiepileptic drugs: a summary of the eighth Eilat Conference (EILAT VIII). Epilepsy Res 73: 1-52. (Pubitemid 46091734)
6. Boxenbaum H, Battle M,. (1995) Effective half-life in clinical pharmacology. J Clin Pharmacol 35: 763-766.
7. Britzi M, Perucca E, Soback S, Levy RH, Faottore C, Crema F, Gatti G, Doose DR, Maryanoff BE, Bialer M,. (2005) Pharmacokinetics and metabolic investigation of topiramate disposition in healthy subjects in the absence and presence of enzyme induction by carbamazepine. Epilepsia 46: 378-384. (Pubitemid 40365643)
8. Doose DR, Streeter AJ,. (2002) Topiramate-chemistry, biotransformation and pharmacokinetics. In, Levy RH, Mattson RH, Meldrum BS, Perucca E, (Eds) Antiepileptic drugs. 5th ed. Lippincott, Williams & Wilkins, Philadelphia, pp. 727-734.
9. Doose DR, Walker SA, Gisclon LG, Nayak RK,. (1996) Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 36: 884-891. (Pubitemid 26384477)
10. Garnett WR,. (2000) Clinical pharmacology of topiramate: a review. Epilepsia 40 (Suppl. 1): S61-S65. (Pubitemid 30202344)
11. Gibaldi M, Perrier D,. (1982) Pharmacokinetics, 2nd ed. Marcel Dekker, New York.
12. Gidal BE,. (2002) Topiramate-drug interactions. In, Levy RH, Mattson TH, Meldrum BS, Perucca E, (Eds) Antiepileptic drugs. 5th ed. Lippincott, Williams & Wilkins, Philadelphia, pp. 735-739.
13. Halvorsen MB, Lambrecht LJ, Boulware MJ, Todd WM,. (2010) Pharmacokinetic equivalence between immediate-release topiramate and USL255, a novel extended-release formulation of topiramate. [AES Abstract 2.176] Presented at the 64th Annual Meeting of the American Epilepsy Society, December 3-7, 2010, San Antonio, TX.
14. Kwan KC, Bohidar NR, Hwang SS,. (1984) Estimation of an effective half-life. In, Benet LZ, Levy G, Ferraiolo B, (Eds) Pharmacokinetics: a modern view. Plenum Press, New York, pp. 147-162.
15. Maryanoff BE, Nortey SO, Gardocki JF, Shank RP, Dodgson SP,. (1987) Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene) β-D-fructopyranose sulfamate and related compounds. J Med Chem 30: 880-887.
16. Mimrod D, Specchio LM, Britzi M, Perucca E, Specchio N, La Neve A, Soback S, Levy RH, Gatti G, Doose DR, Maryanoff BE, Bialer M,. (2005) A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia 46: 1046-1054. (Pubitemid 40962149)
17. Pollak PT, Freeman DJ, Carruthers SG,. (1988) Mean apical concentrations and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations. J Pharm Sci 77: 477-480. (Pubitemid 19036933)
18. Rowland M, Tozer T,. (2010) Clinical pharmacokinetics and pharmacodynamics, 4th ed. Lippincott Williams & Wilkins, Philadelphia.
19. Sachdeo RC, Sachdeo SK, Walker SA, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin DR, Doose DR, Gisclon LG, Bialer M,. (2002) Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43: 691-696. (Pubitemid 34774249)
20. Sahin S, Benet LZ,. (2008) The operational multiple-dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 25: 2869-2877.
21. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schpsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE,. (1994) Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 35: 450-460. (Pubitemid 24138837)
22. Shank RP, Doose DR, Streeter AJ, Bialer M,. (2005) Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. Epilepsy Res 23: 103-112.
23. Todd WM, Lambrecht LJ, Boulware MJ, Halvorsen MB,. (2010) The effect of food on the bioavailability of USL255, a novel extended-release formulation of topiramate. [AES Abstract 2.172] Presented at the 64th Annual Meeting of the American Epilepsy Society, December 3-7, 2010, San Antonio, TX.
24. Wu WN, McKown LA,. (2000) Recent advances in biotransformation of CNS and cardiovascular agents. Curr Drug Metab 1: 255-270.
25. Yamaoka K, Nakagawa T, Uno T,. (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547-558.